Exavir Therapeutics
Exavir Therapeutics is dedicated to transforming the standard of care in long-acting antivirals, focusing on innovative treatments for HIV and related conditions. They develop ultra-long-acting prodrugs and collaborate with partners like ViiV Healthcare to advance their pipeline of antiviral therapies.
Industries
Nr. of Employees
small (1-50)
Exavir Therapeutics
San Francisco, California, United States, North America
Products
Ultra-long-acting cabotegravir prodrug (partner-developed; Phase 1)
A prodrug formulation of an integrase inhibitor engineered for dosing intervals of approximately every six months or longer; clinical development is being conducted by a third-party pharmaceutical partner.
Long-acting dolutegravir prodrug (auto-injector–compatible)
A dolutegravir-based prodrug designed to maintain therapeutic concentrations for extended intervals (up to approximately four months) and formulated to be compatible with self-administration via an auto-injector device.
Ultra-long-acting tenofovir prodrug nanosuspension
A tenofovir prodrug formulated as a nanosuspension to provide sustained levels of the active metabolite (tenofovir-diphosphate) for treatment of HIV, hepatitis B, and HIV–HBV co-infection.
XV-122
XV-122 is a long-acting prodrug of dolutegravir expected to provide therapeutic concentrations of DTG in up to once-every-fourth-month dosing intervals, and to be compatible with self-administration via auto-injector.
VH-310
VH-310 is an ultra-long-acting prodrug of cabotegravir expected to provide dosing intervals of once-every-six-months or longer.
XV-207
XV-207 is a long-acting prodrug of tenofovir expected to provide therapeutic exposure to the active metabolite of tenofovir, tenofovir-diphosphate, for the treatment of HIV, HBV, and HIV-HBV co-infection.
Ultra-long-acting cabotegravir prodrug (partner-developed; Phase 1)
A prodrug formulation of an integrase inhibitor engineered for dosing intervals of approximately every six months or longer; clinical development is being conducted by a third-party pharmaceutical partner.
Long-acting dolutegravir prodrug (auto-injector–compatible)
A dolutegravir-based prodrug designed to maintain therapeutic concentrations for extended intervals (up to approximately four months) and formulated to be compatible with self-administration via an auto-injector device.
Ultra-long-acting tenofovir prodrug nanosuspension
A tenofovir prodrug formulated as a nanosuspension to provide sustained levels of the active metabolite (tenofovir-diphosphate) for treatment of HIV, hepatitis B, and HIV–HBV co-infection.
XV-122
XV-122 is a long-acting prodrug of dolutegravir expected to provide therapeutic concentrations of DTG in up to once-every-fourth-month dosing intervals, and to be compatible with self-administration via auto-injector.
VH-310
VH-310 is an ultra-long-acting prodrug of cabotegravir expected to provide dosing intervals of once-every-six-months or longer.
XV-207
XV-207 is a long-acting prodrug of tenofovir expected to provide therapeutic exposure to the active metabolite of tenofovir, tenofovir-diphosphate, for the treatment of HIV, HBV, and HIV-HBV co-infection.
Services
Out-licensing of long-acting antiviral candidates and collaboration with pharmaceutical partners that assume clinical development and commercialization responsibilities under milestone/royalty agreements.
Execution of preclinical and early-stage program work supported by government grants and awards.
Out-licensing of long-acting antiviral candidates and collaboration with pharmaceutical partners that assume clinical development and commercialization responsibilities under milestone/royalty agreements.
Execution of preclinical and early-stage program work supported by government grants and awards.
Expertise Areas
- Long-acting prodrug development
- Antiretroviral therapeutics (HIV, HBV, co-infection)
- Formulation development for extended-release injectables
- Preclinical PK/PD modeling and prediction
Key Technologies
- Prodrug chemistry for extended release
- Nanosuspension formulation
- Pharmacokinetic modeling
- Auto-injector–compatible formulation design
News & Updates
On May 24, 2024, Exavir Therapeutics announced a license agreement with ViiV Healthcare for ultra-long-acting HIV compounds.
On August 22, 2023, Exavir Therapeutics received a $3 million award from NIH to support the development of XVIR-110.
A publication discussing preclinical assessments of a cabotegravir prodrug by Exavir that predicts human dosing durations of over six months.
A publication on the development of an ultralong-acting dolutegravir prodrug by Exavir.
Exavir announced a license agreement with ViiV Healthcare for their ultra-long-acting HIV compounds.
Received a $3 million award from NIH to advance the ultra-long-acting integrase inhibitor XVIR-110.
On May 24, 2024, Exavir Therapeutics announced a license agreement with ViiV Healthcare for ultra-long-acting HIV compounds.
On August 22, 2023, Exavir Therapeutics received a $3 million award from NIH to support the development of XVIR-110.
A publication discussing preclinical assessments of a cabotegravir prodrug by Exavir that predicts human dosing durations of over six months.
A publication on the development of an ultralong-acting dolutegravir prodrug by Exavir.
Exavir announced a license agreement with ViiV Healthcare for their ultra-long-acting HIV compounds.
Received a $3 million award from NIH to advance the ultra-long-acting integrase inhibitor XVIR-110.